GlassScriptPhysician profile
Michael L Emery
NPI 1215699319
$3,515.10
in general payments reported to CMS, 2019-2025
34 companies · $1,017 in 2025
The $1,017 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $103 · 2022: $803 · 2023: $1,151 · 2024: $442 · 2025: $1,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,609.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $336.32 | 2022-2023 | Cuvitru, Hyqvia |
| Endo USA, INC. | $293.72 | 2024-2025 | Xiaflex, Aveed |
| Genzyme Corporation | $287.29 | 2023 | |
| Teleflex LLC | $254.43 | 2024-2025 | Urolift, Barrigel |
| Abbott Laboratories | $240.66 | 2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $198.00 | 2022-2023 | Tezspire |
| Pharming Healthcare, INC. | $175.96 | 2022-2023 | Ruconest |
| Xeris Pharmaceuticals, INC. | $172.44 | 2021-2022 | |
| Glaxosmithkline, LLC. | $170.52 | 2022-2023 | Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $170.10 | 2022-2023 | Dupixent |
| Antares Pharma, INC. | $157.40 | 2024-2025 | Xyosted |
| Procept Biorobotics Corporation | $103.13 | 2025 | |
| Janssen Biotech, INC. | $98.69 | 2024-2025 | Erleada |
| Novo Nordisk INC | $96.41 | 2025 | Wegovy |
| Tolmar, INC. | $89.00 | 2024-2025 | Eligard |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $87.69 | 2023 | Dexcom G7 Gss (161) |
| Coloplast Corp | $67.24 | 2024-2025 | |
| Abbvie INC. | $57.85 | 2025 | |
| Pfizer INC. | $48.76 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $48.73 | 2025 | Gemtesa |
| Boston Scientific Corporation | $47.39 | 2025 | Accolade Sr, Xpeeda Dsl Fiber |
| Ferring Pharmaceuticals INC. | $31.65 | 2025 | Adstiladrin |
| Kaleo, INC. | $29.68 | 2022-2023 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $28.03 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.33 | 2025 | |
| Octapharma USA, INC. | $26.85 | 2022 | |
| Laborie Medical Technologies Corp. | $26.82 | 2025 | |
| Amgen INC. | $23.77 | 2022 | |
| Telix Pharmaceuticals | $23.27 | 2024 | Illuccix |
| Csl Behring | $22.09 | 2023 | Haegarda |
| Phadia US INC. | $20.72 | 2023 | Immunocap |
| Urogen Pharma, INC. | $20.02 | 2025 | |
| Mylan Specialty L.P. | $17.87 | 2023 | Yupelri |
| Dendreon Pharmaceuticals LLC | $15.27 | 2025 | Provenge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Emery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.